Tramadol: does it have a role in cancer pain management?


Tramadol: does it have a role in cancer pain management?


Prommer EE


Journal Of Opioid Management




Humans; Analgesics; Methadone; Pain/drug therapy/etiology; Neoplasms/complications; Opioid/adverse effects/chemistry/pharmacokinetics/therapeutic use; Tramadol/adverse effects/chemistry/pharmacokinetics/therapeutic use


Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization's guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potentialfor drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug's role in cancer care.


Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).


Journal Article

Citation List Month



Prommer EE, “Tramadol: does it have a role in cancer pain management?,” Pediatric Palliative Care Library, accessed May 29, 2023,